Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

GRK2 inhibition protects against chronic heart failure

Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion, according to two studies conducted at the Center for Translational Medicine at Thomas Jefferson University. The studies will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Fla.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

18 Nov 2009

Maternal blood biomarkers may help predict pregnancy-induced hypertension

A new study that examines the value of maternal blood biomarkers will help identify and monitor patients at risk of developing preeclampsia and is set to change the way expectant mothers are cared for in prenatal clinics around the world.

18 Nov 2009

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.

17 Nov 2009

Second-quarter fiscal 2010 results announced by China-Biotics

China-Biotics, Inc., a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the second quarter of its 2010 fiscal year, ended September 30, 2009.

17 Nov 2009

Illinois and Michigan teens honored at 2009 Siemens Competition

Research projects in the areas of biology and mathematics scored top marks this evening, as Marissa Suchyta of South Barrington, Illinois and the team of Randy Jia of Rochester Hills, Michigan and David Lu of Bloomfield Hills, Michigan received the highest honors at the Region Three Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school science competition.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

New insights into cells' reaction to DNA damage

Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression.

17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Researchers discover a way to boost levels of palmitoylethanolamide

UC Irvine pharmacology researchers have discovered a way to boost levels of a natural body fat that helps decrease inflammation, pointing to possible new treatments for allergies, illnesses and injuries related to the immune system.

17 Nov 2009

New Web-based application for tracking the H1N1 flu virus across the globe

New methods of studying avian influenza strains and visually mapping their movement around the world will help scientists more quickly learn the behavior of the pandemic H1N1 flu virus, Ohio State University researchers say.

17 Nov 2009

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

FDA approves CSL's seasonal and H1N1 flu vaccines for children

The U.S. Food and Drug Administration has approved the use of the CSL Limited's seasonal and 2009 H1N1 influenza vaccines to include children ages 6 months and older. These vaccine were previously approved for use in adults, ages 18 years and older

17 Nov 2009

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

A protein long thought to be a secondary regulator in the heart's response to stressors like hypertension actually appears to be a primary regulator according to researchers from the Center for Translational Medicine at Thomas Jefferson University.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

17 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009